Sensitivity for detection and diagnosis of early (enamel) caries · Asymptomatic children, adolescents, or adults presenting for clinical examination (in vivo studies), or extracted teeth of children or…
1 finding from 1 review
Adverse effects sufficient to stop treatment · women at increased risk of VTE in the early postpartum period
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects sufficient to stop treatment · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes adverse effects sufficient to stop treatment compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Specificity for detection and diagnosis of early (enamel) caries · Asymptomatic children, adolescents, or adults presenting for clinical examination (in vivo studies), or extracted teeth of children or…
1 finding from 1 review
Treatment retention Early dropout · individuals dependent on illicit opiates
Dihydrocodeine showed no clear difference in treatment retention Early dropout compared with buprenorphine (low certainty).
1 finding from 1 review
Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ANXIOLYTIC ‐ BUSPIRONE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether FATTY ACID ‐ ETHYL‐EPA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether HERB ‐ GINKGO BILOBA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether POLYPEPTIDE ‐ CERULETIDE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 35 (mean) years old patients with schizophrenia and tardive dyskinesia, acute extrapyramidal symptoms, and/or…
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes acceptability of the treatment: leaving the study early compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
RR 0.33 [0.06, 1.99]
1 study · 8 participants
Very low
Satisfaction with treatment: leaving the study early Endpoint data (events) · patients with schizophrenia
CBT may leads to lower satisfaction with treatment ‐ leaving the study early for any reason compared with ALL OTHER PSYCHOLOGICAL THERAPIES (low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early ‐ medium term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with depression
Music therapy plus treatment as usual (TAU) showed no clear difference in leaving the study early Up to 3 months compared with TAU (moderate certainty).
1 finding from 1 review